Affiliation:
1. St Jude Children's Research Hospital Memphis Tennessee USA
2. Texas Children's Cancer and Hematology Center Baylor College of Medicine Houston Texas USA
3. Division of Pediatric Hematology and Oncology University of Minnesota Medical Center Minneapolis Minnesota USA
Abstract
AbstractThe Developmental Therapeutics Committee (DVL) identifies and develops new agents and treatment strategies for children/adolescents with cancer, through clinical and translational research. DVL has focused on evaluating the activity of targeted therapy and has evolved from trials with multiple histology strata to biomarker‐selected phase 2 trials. These trials have included single‐agent studies to evaluate agents such as cabozantinib in multi‐disease cohorts, to trametinib, larotrectinib, and lorvotuzumab in disease‐specific cohorts, as well as the pediatric Molecular Analysis for Therapy Choice (MATCH) study including multiple single agents targeted for biomarker‐selected pediatric tumors. The ongoing vision and direction of DVL is to support the disease committees of COG to develop novel agents and combinations to advance the care of children with cancer.
Subject
Oncology,Hematology,Pediatrics, Perinatology and Child Health